The first 60 days: NUT carcinoma (midline carcinoma with NUTM1 rearrangement)
NUT carcinoma is a fast-growing cancer of the midline of the body driven by a single fused gene, BRD4-NUTM1, that locks cells in an immature state. Chemotherapy and surgery rarely control it for long, but drugs that block the BET proteins the fusion depends on have produced responses and are the focus of trials. Below, week by week, is what OnCo's record of NUT carcinoma (midline carcinoma with NUTM1 rearrangement) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Localised.
- Medical oncologistNamed in the standard of care for: Localised, Advanced or relapsed.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Localised, Advanced or relapsed.
- Palliative and supportive care teamNamed in the standard of care for: Advanced or relapsed.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.LocalisedNCI PDQ: childhood midline tract carcinoma with NUT gene changes; International NUT Carcinoma Registry
Multimodality: complete resection where feasible, radiotherapy, and intensive chemotherapy (ifosfamide-based or platinum-based, often Ewing-type regimens); early referral to a centre with NUT carcinoma experience.
Clinical trial of a BET inhibitor (ZEN-3694, NUV-868, molibresib) alone or with chemotherapy; palliative chemotherapy and radiotherapy.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example NUT immunohistochemistry, NUTM1 fusion by FISH or RNA sequencing, Fusion partner, Site), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include BRD4-NUTM1, BRD3-NUTM1, NSD3-NUTM1.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Localised
- For my situation (localised), which of the standard options do you recommend and why?Guideline options include: Multimodality: complete resection where feasible, radiotherapy, and intensive chemotherapy (ifosfamide-based or platinum-based, often Ewing-type regimens); early referral to a centre with NUT carcinoma experience.
- Am I a candidate for Ifosfamide, Cisplatin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced or relapsed
- For my situation (advanced or relapsed), which of the standard options do you recommend and why?Guideline options include: Clinical trial of a BET inhibitor (ZEN-3694, NUV-868, molibresib) alone or with chemotherapy; palliative chemotherapy and radiotherapy.
Any stage
- Are there clinical trials I could join, for example of ZEN-3694, ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2), ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1), Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Misdiagnosis and delay: NUT immunohistochemistry should be routine in poorly differentiated midline tumours”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “BET inhibitor responses are short: degraders, CDK9 and HDAC combinations, and chemotherapy combinations are in trials”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)Phase 2 · recruiting · NCT07050186Incurable metastatic or unresectable NUT carcinoma: single-arm open-label pilot of the PD-1 antibody cemiplimab; started August 2025, 15 planned
- ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)Phase 1/2 · recruiting · NCT05019716Advanced, metastatic or unresectable NUT carcinoma: the BET bromodomain inhibitor ZEN003694 added to platinum-based chemotherapy; started July 2022, 36 planned
- ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)Phase 1 · recruiting · NCT05372640NUT carcinoma, advanced breast cancer and other solid tumours: BET inhibitor ZEN003694 with the CDK4/6 inhibitor abemaciclib; started August 2023, 45 planned
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- NUT carcinoma (midline carcinoma with NUTM1 rearrangement): the full pageNUT carcinoma is a fast-growing cancer of the midline of the body driven by a single fused gene, BRD4-NUTM1, that locks cells in an immature state. Chemotherapy and surgery rarely control it for long, but drugs that block the BET proteins the fusion depends on have produced responses and are the focus of trials.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Gene fusion: A gene fusion is two genes broken and joined together, creating a hybrid protein that can drive cancer.
- Rare cancers: Rare cancers are those with fewer than about 6 new cases per 100,000 people per year.
Every term links to the glossary.